BC
IMDX

Broadwood Capital’s Insight Molecular Diagnostics IMDX Stock Holding History

Broadwood Capital’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.1M Buy
11,931,839
+521,739
+5% +$3.03M 2.76% 6
2025
Q4 		$85.6M Hold
11,410,100
– – 5.03% 5
2025
Q3 		$37.9M Hold
11,410,100
– – 2.28% 6
2025
Q2 		$34.5M Hold
11,410,100
– – 2.2% 6
2025
Q1 		$34.9M Buy
11,410,100
+5,165,695
+83% +$14M 2.83% 5
2024
Q4 		$14.9M Buy
6,244,405
+1,315,339
+27% +$3.58M 1.16% 6
2024
Q3 		$14M Hold
4,929,066
– – 1.08% 6
2024
Q2 		$14.5M Buy
4,929,066
+2,420,000
+96% +$6.65M 1.1% 6
2024
Q1 		$7.35M Hold
2,509,066
– – 0.55% 6
2023
Q4 		$6.27M Hold
2,509,066
– – 0.53% 6
2023
Q3 		$7.83M Sell
2,509,066
-1
-0% -$4 0.7% 6
2023
Q2 		$11.5M Buy
2,509,067
+1,341,382
+115% +$6.76M 0.86% 6
2023
Q1 		$8.28M Hold
1,167,685
– – 0.58% 6
2022
Q4 		$7.49M Hold
1,167,685
– – 0.63% 6
2022
Q3 		$17M Hold
1,167,685
– – 1.3% 7
2022
Q2 		$21M Buy
1,167,685
+300,188
+35% +$6.83M 1.58% 6
2022
Q1 		$25.9M Hold
867,497
– – 1.86% 6
2021
Q4 		$37.6M Hold
867,497
– – 2.31% 6
2021
Q3 		$61.8M Buy
867,497
+28,673
+3% +$2.64M 3.15% 6
2021
Q2 		$96.3M Hold
838,824
– – 4.3% 6
2021
Q1 		$87.1M Buy
838,824
+103,014
+14% +$9.78M 4.63% 5
2020
Q4 		$35.2M Hold
735,810
– – 2.09% 6
2020
Q3 		$20.5M Hold
735,810
– – 1.61% 6
2020
Q2 		$28.1M Buy
735,810
+52,500
+8% +$2.71M 2.2% 6
2020
Q1 		$33.5M Buy
683,310
+69,573
+11% +$3.41M 3.91% 5
2019
Q4 		$27.6M Buy
613,737
+58,824
+11% +$2.12M 3.18% 6
2019
Q3 		$23.3M Buy
554,913
+150,000
+37% +$5.89M 3.24% 6
2019
Q2 		$20.2M Hold
404,913
– – 2.52% 6
2019
Q1 		$32M Buy
404,913
+26,666
+7% +$1.72M 3.92% 6
2018
Q4 		$10.4M Hold
378,247
– – 1.47% 6
2018
Q3 		$18.9M Hold
378,247
– – 1.76% 7
2018
Q2 		$19.3M Hold
378,247
– – 2.22% 7
2018
Q1 		$15.9M Buy
378,247
+198,413
+110% +$13.1M 2.31% 7
2017
Q4 		$16.7M Hold
179,834
– – 2.33% 7
2017
Q3 		$27.2M Buy
179,834
+27,000
+18% +$2.83M 4.5% 5
2017
Q2 		$15.9M Hold
152,834
– – 2.92% 5
2017
Q1 		$18.2M Buy
152,834
+21,250
+16% +$2.45M 3.47% 5
2016
Q4 		$18.6M Hold
131,584
– – 3.15% 6
2016
Q3 		$13.3M Buy
131,584
+76,923
+141% +$6.21M 2.27% 8
2016
Q2 		$3.89M Hold
54,661
– – 0.75% 9
2016
Q1 		$5.04M Buy
+54,661
New +$4.84M 1.04% 9

Other funds holding IMDX

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
FOR
Family Office Research Bethesda, Maryland $230M AUM 23.5% 1-Year Est. Return

Broadwood Capital's IMDX Position: Q1 2026 in Review

Broadwood Capital increased its Insight Molecular Diagnostics (IMDX) stake by 4.6% in Q1 2026, buying an estimated $3.03M and bringing the position to 11,931,839 shares worth $39.1M. The position accounts for 2.76% of the portfolio, ranked #6.

Broadwood Capital first reported a position in IMDX in Q1 2016 and has held it in 41 quarters since. The position peaked at $96.3M in Q2 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Broadwood Capital held 11,931,839 shares of Insight Molecular Diagnostics worth $39.1M as of Q1 2026.
  • Broadwood Capital bought 521,739 Insight Molecular Diagnostics shares in Q1 2026, an estimated $3.03M.
  • Insight Molecular Diagnostics made up 2.76% of Broadwood Capital's portfolio in Q1 2026, its #6 holding.
  • Broadwood Capital first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 41 quarters since.
  • Broadwood Capital's Insight Molecular Diagnostics position peaked at $96.3M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Broadwood Capital's 13F filing for Q1 2026, filed 15 May 2026.